Extensive activities took place on international health over the past decade 6 focusing renewed attention and possible interventions to reduce global burden of U-5 mortality and morbidity. 5 But, pneumonia remains neglected 1 with a little attention paid on to it 1, 6 including essential research and vaccine trials. 7 As a result, worldwide U-5 pneumonia death still persists to be unacceptably high 3 particularly in least developed countries (LDC). 2 Global estimation revealed 150 million pneumonia episodes/year among U-5 children in developing countries, accounting for > 95% of all new cases worldwide, 11 to 20 million of which require hospitalization. 8 Around 19% [3] [4] of these occur in mere 42 developing While south Asian and sub-Sahara countries bear the burden of >half 8 of total U-5 pneumonia episode worldwide; 3 / 4 th of these occur in mere 15 countries 8 -where Bangladesh ranks 4 th with 6 million pneumonia cases. 1, 8 Incidence of ALRI (mostly pneumonia) related hospital admission among U-5 in rural Bangladesh is 50.2/child-year-observed. 10 Interestingly, U-5 mortality in Bangladesh though came down from 150 in 1965 to 68 in 2007, [11] [12] pneumonia incidence still remains very high 13 (47% of U-5 illness 14 ) including deaths (23% 15, 16 ) which may escalate even more if neonatal pneumonia death of ~10% is added. [14] [15] [16] Pneumonia due to Strept. pneumoniae alone kills 1 million U-5 children annually, 17 mojority being among <2 years children of LDC, as WHO estimated recently. 16, 17 Average annual mortality for children under givers. The awareness mainly aimed at early case detection, quick referral and providing appropriate treatment. These activities also extended upto family level to empower the caregivers with sufficient knowledge in addressing common problems and deciding when to transport the child to a health care facility with more extensive supervised care. These measures proved to have significant impact in reducing U-5 mortality.
Current findings from hospital and community based studies underscored the need for preventive strategies as in adjunct to accurate clinical approach, improved diagnostic tools and perfect treatment regimen. 5 But these may hamper due to lack in gold standard in current algorithms (insufficient specificity) and lack in classic microbiological methods (poor sensitivity). 5 It is also essential to combine vaccines with particular emphasis on appropriate use of antibiotics in pneumonia prevention programs. 5, 26, 27 Meanwhile, Hib-vaccine trial conducted in different countries has shown considerable reduction in pneumonia incidence. GOB has recently introduced Global Alliance for Vaccine and Immunization (GAVI) -funded penta-valent vaccine (DPT, Hepatitis-B and Hib) with a target of not only reducing pneumonia deaths but also preventing ~90% of Hib-meningitis and others. 16 But, Bangladeshi children will still die of pneumonia due to a major pathogen, Strept. pneumoniae 21 which remains uncovered to several serotypes. 16 Thus, in Bangladesh, where care seeking behavior remains poor and access to health care facilities is hard-to-reach, it is imperative that Govt. of Bangladesh should take prompt initiative to introduce pneumococcal vaccine under EPI though its formulation remains challenging as Streptococcus pneumoniae has 90 serotypes having geographically diverse and immunologically distinct characteristics. 1, 7, 21-22 Currently available 7-valent pneumococcal vaccine is customized based on the predominant serotypes of industrialized countries. 17 So, vaccines need to be customized according to our need by gathering further information about circulating invasive pneumococcal serotypes in Bangladesh and neighboring regions to facilitate accurate formulation of next generation pneumococcal vaccine which we expect to be available soon with the active support from GAVI, to help bring down U-5 pneumonia death significantly.
However a huge budgetary involvement in procuring such a vaccine remains a potential constraint. The GOB should seek financial/technical assistance form donors/UN agencies for this approach. However, a new vaccine grant by GAVI is only $0.30/infant in the birth cohort/year or minimum $100,000. 28 GOB essentially needs a defined strategy, a robust work plan and a strong political will to make such a vaccination procurement project, cost-effective and sustainable.
Anticipating the huge consumption of pneumococcal vaccine in Bangladesh where birth cohort is~4%, it will be more cost-effective, if the GOB can start manufacturing this vaccine on its own capacity through transfer of technology. At the same time it will exert a positive impact in our national economy through industrialization and thus creating scope of employment, at least in part.
